Recent Company News

• 11:39 AM ET Apr 16, 2026
  

  FDA taking an initial step to advance testosterone therapy for men

• 11:38 AM ET Apr 16, 2026
  

  FDA announces new indication for TRT use in low libido men; asks drugmakers to contact agency about sNDA opportunity

• 10:37 AM ET Apr 16, 2026
  

  Appeals court reverses and remands court ruling finding Teva's headache patents invalid in litigation with Eli Lilly ($31.49, -0.12)

• 09:15 AM ET Apr 16, 2026
  

  Scotiabank research highlights best-in-class commercial organizations in biopharma

• 07:59 AM ET Apr 15, 2026
  

  Teva Launches Home Ground(TM) Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners

• 08:34 AM ET Apr 14, 2026
  

  Neurocrine Biosciences presents first real-world head-to-head claims analysis of INGREZZA (valbenazine) capsules compared to AUSTEDO XR ($126.32, 0.00)

• 08:00 AM ET Apr 14, 2026
  

  Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics

• 03:08 AM ET Apr 13, 2026
  

  H. Lundbeck to showcase new neurology data at the American Academy of Neurology Annual Meeting (DKK 40.36, -0.02)

• 08:02 AM ET Mar 30, 2026
  

  Teva Pharmaceutical announces FDA approval of PONLIMSI and dual filing acceptance for biosimilar candidate to Xolair ($28.74, 0.00)

• 08:00 AM ET Mar 30, 2026
  

  Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI(TM) (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair(R) (omalizumab)